Lastly, the development and clinical evaluation of a specific HIF2α inhibitor, Belzutifan, represents another opportunity to assess the necessity of HIF2α activity for the various clinical manifestations associated with VHL disease (Cho et al., 2016; Chen et al., 2016). Here, EPAS1 is linked to von Hippel-Lindau disease.